Bryan Moyer

Bryan has more than 20 years of experience in research and development, with an established record leading drug discovery teams for target identification/validation, target engagement in translatable models of human disease and clinical candidate delivery. He co-founded Latigo Biotherapeutics where he led the discovery organization to deliver two clinical candidates targeting Nav1.8. Prior to Latigo, and during his ten-year tenure at Amgen, he led multi-modality discovery programs to advance small molecule, peptide, and antibody-based therapeutics for pain and migraine indications. Prior to Amgen, Bryan was at Senomyx, a biotechnology company working on taste biology, where he led drug discovery and target identification efforts for taste receptors and transmembrane targets. Bryan has a B.S. in Animal Physiology and Neuroscience from the University of California, San Diego, a Ph.D. in Physiology from Dartmouth Medical School, and completed his postdoctoral fellowship at The Scripps Research Institute in La Jolla, California.